What we do

ExQor’s drug platform crosses the blood brain barrier.  The blood brain barrier protects the brain. But the same barrier also prevents almost all drug treatments from gaining access to the brain

The barrier thus severely limits the creation and delivery of drugs to treat CNS diseases and disorders. The use of large molecule biologics is essentially barred. 

ExQor is using a new type of bio-nanotechnology platform that solves the problem of small molecule and large molecule delivery to the CNS.

ExQor's CNS platform is able to target specific regions in the brain with new types of drugs that solve unmet medical needs, including aging of the brain.

ExQor has multiple allowed patents and patents pending on its bio-nanotechnology.


ExQor's bio-nanotechnology platform non-invasively delivers large molecule biologics to the brain and in therapeutically effective amounts. Among them are antibodies, growth factors, and also other types of large and small molecule agents.

ExQor's new drugs are used to treat CNS disorders, some of which have no effective treatments. One new ExQor drug also can exert positive affects against aging and its associated telomere shortening.

ExQor is also developing new types of non-radioactive MRI imaging agents for the brain that are as powerful and effective as radioactive tracers used in positron emission tomography (PET).

ExQor's therapeutics and imaging agents also can be combined into a single composition, which is called a theranostic.

Our Results

  • Alzheimer’s
  • ExQor’s preclinical in vivo results of delivering a biologic, brain derived neurotrophic factor (BDNF), to the CNS show success in treating Alzheimer’s Disease. Currently, there are no effective treatments for Alzheimer’s.

  • HIV-1
  • ExQor’s preclinical in vivo results of BDNF delivery to the CNS show success in treating HIV-1 associated neurocognitive disorders (HAND). Currently, there are no effective treatments for HAND.

    ExQor is now in the FDA planning stages for its Alzheimer’s and HAND drugs.

  • COVID-19
  • COVID-19 causes neurological and cognitive deficits in a substantial proportion of affected patients. These deficits also can be long term. Before or after FDA allowance of its HIV-1 drug for the CNS ExQor is going to repurpose it to treat and prevent the neurological damage caused by COVID-19.

  • Drug Addiction
  • ExQor’s preclinical in vivo results show that antibody targeted delivery of BDNF to specific regions of brain reverses damage caused by METH addiction. Currently, there are no effective treatments for reversing this damage.




    © 2020 ExQor Technologies, Inc . All rights reserved.